Indeed, topical application of LXA4 reduces the severity of childhood AD and improves the quality of life through controlling skin inflammation by downregulating TLR4, p-ERK1/2, and NF-κB signaling, and proinflammatory cytokines [214,215]. This evidence concerns the gene NFKB1 and Alzheimer disease.